Search clinical trials for: PERTUZUMAB

Total 302 results

West German Study Group
Roche Pharma AG

Recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (ADAPT)

Breast Cancer

Germany
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
Genentech, Inc.
Hoffmann-La Roche

Recruiting

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Neoplasm Metastasis

Australia, Korea, Republic of, China, United States, Portugal, Brazil, Singapore, Spain, United Kingdom, Belgium, Austria, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Me... and more
Genentech, Inc.

Active, not recruiting

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Breast Cancer | Solid Tumor

United States, France, Spain, United Kingdom, Canada
Alliance Foundation Trials, LLC.
Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaborators

Active, not recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)

HER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
Hoffmann-La Roche
Foundation Medicine, Inc.

Active, not recruiting

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)

Cancer of Unknown Primary Site

United Kingdom, Korea, Republic of, France, Australia, Germany, Austria, Croatia, Denmark, Finland, Greece, Hungary, Italy, Portugal, Spain, Japan, Brazil, Colombia, Mexico, Romania, Czechia, Norway, Thailand, Switzerland, Turkey, Nethe... and more
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
AstraZeneca
Daiichi Sankyo

Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Breast Cancer; HER2-positive; Metastatic

United States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
Hoffmann-La Roche

Active, not recruiting

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

HER2-positive Early Breast Cancer

China
AstraZeneca
Daiichi Sankyo Company, Limited

Active, not recruiting

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07)

Metastatic Breast Cancer

United States, Italy, India, Taiwan, Germany, Korea, Republic of, Brazil, Poland, Russian Federation, Turkey, Spain, Australia, France, Canada, United Kingdom
University of Kansas Medical Center

Terminated

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

HER2-positive Breast Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
Dana-Farber Cancer Institute
MacroGenics; Translational Breast Cancer Research Consortium

Active, not recruiting

MARGetuximab Or Trastuzumab (MARGOT) (MARGOT)

Breast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage III Breast Cancer

United States
Prof. Wolfgang Janni
Roche Pharma AG; Novartis Pharmaceuticals; Celgene Corporation; Eisai GmbH

Active, not recruiting

Detect V / CHEVENDO (Chemo vs. Endo)

Metastatic Breast Cancer

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Dana-Farber Cancer Institute

Active, not recruiting

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Breast Cancer

United States
Eli Lilly and Company

Active, not recruiting

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial Cancer

United States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
Bolt Biotherapeutics, Inc.
Hoffmann-La Roche

Active, not recruiting

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Metastatic Breast Cancer | HER2-positive Breast Cancer

Spain, United States, Italy
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (EPIK-B2)

Advanced HER2+Breast Cancer

Belgium, France, China, Italy, Spain, Malaysia, United States, Turkey
Caigang Liu
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Hoffmann-La Roche
Latin American Cooperative Oncology Group

Active, not recruiting

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Breast Cancer

Colombia, Guatemala, Argentina, Brazil, Chile, Cuba, Mexico, Peru, Uruguay, Dominican Republic
Nancy Lin, MD
Genentech, Inc.

Active, not recruiting

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

HER2-positive Metastatic Breast Cancer | Central Nervous System Metastases

United States
Hoffmann-La Roche

Completed

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (MODUL)

Colorectal Cancer

Italy, Korea, Republic of, United Kingdom, Belgium, Argentina, Denmark, Greece, Netherlands, Slovenia, Spain, Sweden, Turkey, Brazil, Bosnia and Herzegovina, France, Germany, Portugal, Egypt, Poland, Slovakia, Mexico, Serbia, Russian...
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
AstraZeneca
Daiichi Sankyo

Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Breast Cancer | Breast Neoplasms | HER2-positive Early Breast Cancer

United States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC; Breast Cancer Research Foundation

Active, not recruiting

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

Breast Cancer | HER2-positive Breast Cancer

United States
Qilu Pharmaceutical Co., Ltd.

Completed

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Breast Cancer

China
Palleos Healthcare GmbH
Roche Pharma AG; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP

Completed

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (TP-II)

Breast Neoplasms

Germany
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

Inflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Canada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
Shanghai Henlius Biotech

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer

China
Hoffmann-La Roche

Active, not recruiting

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Solid Tumor

Korea, Republic of, China, France, Portugal, Spain, Brazil, Germany, Italy, Peru, Russian Federation, Japan, Ukraine, Costa Rica, Mexico, Poland
The Netherlands Cancer Institute
Roche Pharma AG; Borstkanker Onderzoek Groep

Active, not recruiting

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (TRAIN-2)

Breast Cancer | HER2 Positive

Netherlands
Eli Lilly and Company

Active, not recruiting

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Breast Neoplasms

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Breast Adenocarcinoma | Inflammatory Breast Carcinoma

United States
MedSIR
Hoffmann-La Roche

Active, not recruiting

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)

Early Breast Cancer

Spain, Italy, Germany, Bulgaria, Hungary
Genentech, Inc.

Completed

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)

Advanced Unresectable or Metastatic Solid Malignancy

United States
Fondazione Michelangelo
Hoffmann-La Roche

Active, not recruiting

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)

Invasive Breast Cancer

Spain, Italy, Germany, Austria
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Hoffmann-La Roche
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Breast Cancer

United States, Italy, United Kingdom, Australia, Austria, Belgium, Brazil, Denmark, France, Guatemala, Korea, Republic of, Portugal, Spain, Turkey, Colombia, Canada, Czechia, Japan, Poland, Romania, Russian Federation, Switzerland, ... and more
Dana-Farber Cancer Institute
Genentech, Inc.

Active, not recruiting

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Breast Cancer | Stage II Breast Cancer | HER-2 Positive Breast Cancer | Stage III Breast Cancer

United States
Otto Metzger, MD
Genentech, Inc.

Active, not recruiting

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Metastatic Breast Cancer | Recurrent Breast Cancer

United States
Mabscale, LLC

Active, not recruiting

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

Healthy Men

Russian Federation
Henan Cancer Hospital

Withdrawn

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Fudan University

Completed

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Breast Cancer

China
Fudan University

Active, not recruiting

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Breast Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Malignant Solid Neoplasm

United States
Genentech, Inc.

Completed

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Neoplasms | Bladder Cancer | Solid Tumors | Biliary Cancer | Salivary Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.; Translational Breast Cancer Research Consortium

Active, not recruiting

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Breast Cancer

United States

Search clinical trials for: PERTUZUMAB

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations